Related Experiment Videos
Activities of tRNA-embedded dimeric minizymes
T Kuwabara1, M Warashina, A Nakayama
1National Institute for Advanced Interdisciplinary Research, Agency of Industrial Science and Technology, Tsukuba Science City, Japan.
Nucleic Acids Symposium Series
|January 1, 1997
Summary
Engineered dimeric ribozymes effectively cleave BCR-ABL mRNA for potential CML treatment. Embedding these minizymes within tRNA enhances their activity compared to conventional hammerhead ribozymes.
Area of Science:
- Molecular Biology
- Gene Therapy
- Biochemistry
Background:
- Ribozymes are potent gene expression inhibitors.
- Dimeric minizymes show high activity and target specific mRNA.
- Efficient in vivo expression is crucial for therapeutic applications.
Purpose of the Study:
- To enhance in vivo expression of dimeric minizymes for Chronic Myeloid Leukemia (CML) treatment.
- To evaluate the cleavage activity of tRNA-embedded dimeric minizymes.
- To compare the efficacy of tRNA-embedded dimeric minizymes with conventional hammerhead ribozymes.
Main Methods:
- Construction of dimeric minizymes targeting BCR-ABL chimeric mRNA.
- Embedding dimeric minizymes downstream of a tRNA(Val) promoter for RNA polymerase III recognition.
- Determination and comparison of cleavage activities of various ribozyme constructs in vitro.
Main Results:
- All tRNA-embedded dimeric minizymes successfully cleaved the target substrate.
- The activity of tRNA-embedded dimeric minizymes targeting BCR-ABL mRNA was comparable to naked dimeric minizymes.
- tRNA-embedded dimeric minizymes exhibited higher cleavage activity than tRNA-embedded conventional hammerhead ribozymes.
Conclusions:
- tRNA-embedding is an effective strategy to enhance ribozyme activity and expression.
- Dimeric minizymes show promise as therapeutic agents for CML by targeting BCR-ABL mRNA.
- This approach offers a potential improvement over conventional hammerhead ribozymes for gene silencing therapies.